UNS unilife corporation

What's next?, page-4

  1. 1,266 Posts.
    TDA,
    nice post. If I might add, JMHO from experience in a different industry.
    Credit is to due getting a new facility built.
    Credit is due to attract top talent to a start up company.
    Credit is do to develop a platform of medical devices that are not standard to
    existing medical devices. New features functionality.
    Credit is due to invest $ RD to attract top pharm's to the table,
    customize devices on our dime to meet the needs of these pharm.'s.
    Credit is due to hold the course focus on the longer term objectives rather than the short term
    gains.
    Credit is due to secure supply agreements from larger established players.
    Credit is due to develop new devices, Imperium-1ml wearable amiss the drums beats of anger
    Credit is due to listen to the needs of the customer.
    Credit is due to the existing supply agreements and other programs undefined.

    Now the focus is turn the above into a sustainable business enterprise. While the clear revenue stream and growth is still unknown, the focus on cost structure will accelerate while the revenue stream is "expected to begin (Mid 2017)" Expect Rev per employee to be a key metric.

    The existing company over head will need to be reduced or overlaid against a rapid growth stream.
    250 employees. Each needs to be matched against a value stream. All business expenses that are perceived to be a perk need to be eliminated. Small annual amount put it sends a clear signal that it's no longer business as usual.

    I support that process that new customers will absorb the cost of customization or at least 50/50 split.
    Or supply contract comes with a large upfront plus profit margin on development costs.

    These pharma's don't waste time. They stay in the game because they see value. Have a business need.
    I offer that the heavy lifting is done and a new chapter of the UNS story in about to unfold.

    Company's make mistakes. Missed opportunities, learned from it and go on. The business landscape is littered with failed companies. Harvard writes hundreds on business cases on them. We all know them.

    Then there is those that win amongst all odds. UNS is in that camp. Pareatos' law is about to begin.

    I await the road map. Best RRM
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.